Dr. Jeffrey E. Gershenwald, MD

Dr. Gershenwald practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Gershenwald's NPI, 1760589162, was assigned on September 20, 2006. Dr. Gershenwald graduated from Weill Cornell Medicine in 1990. Dr. Gershenwald holds Texas license J8247.

Dr. Gershenwald's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Gershenwald's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Gershenwald practices. Vendor and product names are available with a free account.

Surgical oncology is Dr. Gershenwald's primary specialty in the NPI Registry, under taxonomy code 2086X0206X. Dr. Gershenwald is board certified in surgery by the American Board of Surgery. Dmand AI has Dr. Gershenwald's licenses on file in 10 states: Texas, Arizona, Georgia, New York, Oklahoma, Tennessee, Alabama, Louisiana, Mississippi and Washington.

Dmand AI lists cancerous skin growth removal among the conditions Dr. Gershenwald treats.

CMS data shows 30 Medicare services from Dr. Gershenwald across 2 procedure codes in 2023, for 32 Medicare patients. Medicare paid $2,621 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 32 Medicare patients who saw Dr. Gershenwald in 2024. The largest group is 75 to 84, with 17 patients. 75% of them have high cholesterol, and 69% have high blood pressure. Their average risk score is 0.97, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Gershenwald's median patient age at 73, with 36% women.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Gershenwald for performance year 2024, reported as part of a group. Dr. Gershenwald accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS counts 47 procedures of melanoma (skin cancer) excision by Dr. Gershenwald, more than 86% of the clinicians it reports for that procedure.

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 321 papers to Dr. Gershenwald, published from 2004 to 2025. 2018 was the busiest year, with 20. The most frequent topics are Melanoma, Skin Neoplasms and Lymphatic Metastasis. Dr. Gershenwald has published most often in Ann Surg Oncol. Dr. Gershenwald's most frequent co-authors are Jeffrey E. Lee, MD, Victor G. Prieto, MD, PhD and Michael A. Davies, MD, PhD.

Dmand AI links Dr. Gershenwald to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Melanoma and Nevi and Melanomas.

CMS Open Payments shows 96 general payments to Dr. Gershenwald from 7 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 80% of the total. Merck Sharp & Dohme Corporation paid the most, $66,912. It also lists 1 research payment totaling $10,779 in 2019.

Dmand AI lists 5 awards for Dr. Gershenwald, most recently Honorary Fellow, Royal Australasian College of Surgeons (RACS) in 2021.

Dr. Gershenwald graduated from Weill Cornell Medicine in 1990. Dr. Gershenwald is a member of ACS and ASCO.

Dr. Gershenwald is in network with 15 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. HMO plans come from the most carriers, 10. Check the plan with the practice before a visit.